Company Filing History:
Years Active: 2006
Title: Børge Teisner: Innovator in Immunoglobulin Production
Introduction
Børge Teisner is a notable inventor based in Odense C, Denmark. He has made significant contributions to the field of immunology through his innovative processes for producing immunoglobulins. His work has implications for intravenous administration and the development of immunoglobulin products.
Latest Patents
Børge Teisner holds a patent for a process for producing immunoglobulins for intravenous administration and other immunoglobulin products. This invention relates to a method for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. The process includes several steps, with anion exchange chromatography and cation exchange chromatography connected in series. An acetate buffer with a pH of about 5.0-6.0 and a molarity of about 5-25 mM is used throughout the purification process. The resulting immunoglobulin product boasts a purity of more than 98%, a content of IgG monomers and dimers exceeding 98.5%, and a content of IgA less than 4 mg of IgA/l. Additionally, it contains less than 0.5% polymers and aggregates, and does not include detergent, PEG, or albumin as stabilizers. This product is stable, virus-safe, liquid, and ready for instant intravenous administration.
Career Highlights
Throughout his career, Børge Teisner has worked with prominent organizations such as Statens Serum Institut and CSL Behring AG. His experience in these institutions has allowed him to refine his expertise in immunology and contribute to advancements in the field.
Collaborations
Børge Teisner has collaborated with various professionals, including his coworker Inga Laursen. Their joint efforts have furthered research and development in immunoglobulin production.
Conclusion
Børge Teisner's innovative work in the purification of immunoglobulins has made a significant impact on the field of immunology. His patent reflects a commitment to advancing medical science and improving patient care through effective immunoglobulin products.